Your choice today can shape your patients’ future.

Choose the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surfacea with 100% freedom from acute limb ischemia (ALI)1 at 5 years and with 79.1% freedom from target lesion revascularization (fTLR)2 at 5 years, for long-lasting intervention-free outcomes.

When every procedure counts, what does long-term durability mean for you and your patients with complex superficial femoral artery (SFA) disease?

SFA disease is a leading cause of symptomatic peripheral artery disease (PAD), including intermittent claudication and chronic limb-threatening ischemia.3,4

Mineral green
Mineral green
Mineral green
Endovascular intervention is an established procedure for the management of SFA disease.5-10
Red Gore
Red Gore
Red Gore
However, as high as 40% Restenosis rates at 12 months are seen with conventional techniques such as balloon angioplasty and bare metal stenting.5–10
Blue stone
Blue stone
Blue stone
This creates a potential burden for patients and health care systems.5–10

Lesion complexity has been shown to drive the costs of SFA endovascular interventions. Despite the wide range of treatment options available, chronic total occlusions (CTOs) and calcification may continue to contribute to the burden on health care systems.11–13 This highlights the need for endovascular devices engineered to withstand the anatomical demands of the SFA and slow disease progression, ultimately helping to maximize the potential for long-term intervention-free outcomes.11–13

As a flexible, self-expanding endograft, the VIABAHN® Device is designed for the treatment of de novo or restenotic lesions, as well as in-stent restenosis (ISR) of the SFA and proximal popliteal artery, with demonstrated durability and reliable performance for up to 5 years.1,9,14,15

The VIABAHN® Device has been purposefully designed to deliver durable outcomes and unmatched versatility.b,1,16

Close-up image of a clinician's hand placed over a patient’s hands.
Proven procedural success

Delivers durable long-term performance in complex SFA lesions.1,9

Explore the clinical data
Close-up image of a hand holding the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface stent graft device
Designed with purpose

Designed by the experts to deliver reliable long-term performance in SFA treatment.1

Find out more

Could the VIABAHN® Device provide true value for you and your patients in complex SFA cases?

With proven long-term performance, the VIABAHN® Device is a trusted endovascular option for treating SFA disease.1,17

a. As used by Gore, PROPATEN Bioactive Surface refers to Gore’s proprietary CBAS® Heparin Surface.
b. Across indications and configurations of covered stents.

  1. Iida O, Ohki T, Soga Y, et al. Five-year outcomes of the GORE® VIABAHN® Endoprosthesis for the treatment of complex femoropopliteal lesions from a Japanese postmarket surveillance study. Vascular Medicine 2024;29(4):416–423. 
  2. Ohki T, Kichikawa K, Yokoi H, et al. Long-term results of the Japanese multicenter VIABAHN® trial of heparin bonded endovascular stent grafts for long and complex lesions in the superficial femoral artery. Journal of Vascular Surgery 2021;74(6):1958-1967.e2.
  3. Schwartz A, Shah Y, Huang H, et al. Comparison of endovascular interventions for the Treatment of superficial femoral artery Disease: A network meta-analysis. Journal of the Society for Cardiovascular Angiography & Interventions 2025;4(1):102432.
  4. Zhang L, Bao J, Zhao Z, et al. Effectiveness of VIABAHN® in the treatment of superficial femoral artery occlusive disease: A systematic review and meta-analysis. Journal of Endovascular Therapy 2015;22(4):495–505.
  5. Schillinger M and Minar E. Percutaneous treatment of peripheral artery disease. Circulation 2012;126(20):2433–2440.
  6. Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: The DEBATE-SFA randomised trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). Journal of the American College of Cardiology: Cardiovascular Interventions 2013;6(12):1295–1302.
  7. Chalmers N, Walker P, Belli A, et al. Randomised trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: The SUPER Study. Cardiovascular & Interventional Radiology 2013;36(2):353–361.
  8. Zielinski L, Chowdhury M, Coughlin P, et al. Patient and institutional costs of failure of angioplasty of the superficial femoral artery. Annals of Vascular Surgery 2021;72:218–266.
  9. Bosiers M, Deloose K, Callaert J, et al. Stent-grafts are the best way to treat complex in-stent restenosis lesions in the superficial femoral artery: 24-month results from a multicenter randomized trial. The Journal of Cardiovascular Surgery 2020;61(5):617–625.
  10. Lammer J, Zeller T, Hausegger KA, et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: The VIASTAR Trial. Cardiovascular & Interventional Radiology 2015;38(1):25–32.
  11. Magnuson E, Li H, Vilain K, et al. Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360° trial. Journal of Medical Economics 2021;24(1):570–580.
  12. Walker K, Nolan B, Columbo J, et al. Lesion complexity drives the cost of superficial femoral artery endovascular interventions. Journal of Vascular Surgery 2015;62(4):998–1002.
  13. Tokuda T, Oba Y, Koshida R, et al. The impact of femoropopliteal artery calcium score after endovascular treatment. Annals of Vascular Surgery 2020;66:543–553.
  14. Gore Medical Products Instructions for Use (IFU). W. L. Gore & Associates, Inc. Accessed May 5, 2026. https://eifu.goremedical.com/
  15. Soukas P, Becker M, Stark K, et al. Three-Year Results of the GORE® VIABAHN® Endoprosthesis in the Superficial Femoral Artery for In-Stent Restenosis. Journal of the Society for Cardiovascular Angiography & Interventions 2023;2(3):100598.
  16. Data on file 2026; W. L. Gore & Associates, Inc; Flagstaff, AZ.
  17. Data on file 2025; W. L. Gore & Associates, Inc; Flagstaff, AZ.
IFU Consult instructions

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

INDICATIONS FOR USE IN EUROPE: The GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface is indicated for the treatment of:

  • de novo or restenotic lesions in the iliac arteries
  • de novo or restenotic lesions in the superficial femoral artery and proximal popliteal artery
  • in-stent restenotic lesions in the superficial femoral artery and proximal popliteal artery
  • stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access grafts and in the venous outflow of dialysis access circuits, including the central veins
  • popliteal artery aneurysms and isolated visceral artery aneurysms
  • traumatic or iatrogenic vessel injuries in arteries that are located in the chest cavity, abdominal cavity or pelvis (except for aorta, coronary, innominate, carotid, vertebral and pulmonary arteries)

CONTRAINDICATIONS:

  • Non-compliant lesions where full expansion of an angioplasty balloon catheter was not achieved during pre-dilatation, or where lesions cannot be dilated sufficiently to allow passage of the delivery system.
  • Do not use the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface in patients with known hypersensitivity to heparin, including those patients who have had a previous incidence of Heparin-Induced Thrombocytopenia (HIT) type II.
Products may not be available in all countries. Please check with your Gore representative for availability.
26PL2034-EN01 MAT-0337-1